Adderall 7.5 Patent Expiration

Adderall 7.5 is a drug owned by Teva Womens Health Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 06, 2021. Details of Adderall 7.5's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6384020

(Pediatric)

Rapid immediate release oral dosage form
Jan, 2021

(3 years ago)

Expired
US6384020 Rapid immediate release oral dosage form
Jul, 2020

(4 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Adderall 7.5 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adderall 7.5's family patents as well as insights into ongoing legal events on those patents.

Adderall 7.5's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Adderall 7.5's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 06, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Adderall 7.5 Generic API suppliers:

Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate is the generic name for the brand Adderall 7.5. 30 different companies have already filed for the generic of Adderall 7.5, with Actavis Elizabeth having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adderall 7.5's generic

How can I launch a generic of Adderall 7.5 before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Adderall 7.5's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Adderall 7.5's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Adderall 7.5 -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
5 mg, 10 mg, 20 mg, 30 mg 18 Nov, 2009 1 06 Jul, 2020 Extinguished
7.5 mg, 12.5 mg and 15 mg

Alternative Brands for Adderall 7.5

There are several other brand drugs using the same active ingredient (Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate) as Adderall 7.5. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.


Apart from brand drugs containing the same ingredient, some generics have also been filed for Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate, Adderall 7.5's active ingredient. Check the complete list of approved generic manufacturers for Adderall 7.5





About Adderall 7.5

Adderall 7.5 is a drug owned by Teva Womens Health Inc. Adderall 7.5 uses Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate as an active ingredient. Adderall 7.5 was launched by Teva Womens in 1996.

Approval Date:

Adderall 7.5 was approved by FDA for market use on 13 February, 1996.

Active Ingredient:

Adderall 7.5 uses Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate as the active ingredient. Check out other Drugs and Companies using Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate ingredient

Dosage:

Adderall 7.5 is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
1.875MG;1.875MG;1.875MG;1.875MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET Discontinued ORAL